Bio­gen fi­nal­ly pub­lish­es PhI­II re­sults for Aduhelm as crit­ics chas­tise low-rank­ing jour­nal, ‘gen­tle and un­re­veal­ing’ peer re­view

Bio­gen qui­et­ly an­nounced at a con­fer­ence in Spain to­day that a man­u­script of the Phase III re­sults for the com­pa­ny’s con­tro­ver­sial Alzheimer’s drug Aduhelm has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.